Komori
Stella Pharma (4888) · InitiativeRestated

Enhancing Transparency in the Executive Appointment Process through the Nomination and Compensation Committee

First written in FY2025. 1 of 2 entries say "Restated". Latest entry: FY2026.

2entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2025 – FY20262025: 120252026: 12026
Same theme, other companies
Operation of the Nomination and Compensation Committee Centered on Independent Outside DirectorsA theme 185 companies write about · 0 as a headwind · 185 as a tailwind

The whole theme swung hardest in 2025: 9 of 86 companies on the "Worse" side.

83 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 185 companies compared. The sentences above are computed from all 185.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「Our Nomination and Compensation Committee consists of 4 members, chaired by Representative Director and President Uehara Koki (上原 幸樹), and comprising Outside Director and Audit and Supervisory Committee Member Onishi Masaya (大西 雅也), Outside Director and Audit and Supervisory Committee Member Tsujii Kohei (辻井 康平), and Outside Director and Audit and Supervisory Committee Member Fukuchi Toshiyuki (福地 叔之). When the Board of Directors decides on executive appointments, compensation and other matters, the Nomination and Compensation Committee, an advisory body to the Board comprising a majority of outside directors, deliberates on the matters, and decisions are made through a process with greater transparency and objectivity.」

    The executive decision-making process continues to operate through a 4-member Nomination and Compensation Committee in which outside directors comprise a majority.
  2. FY2025First statedAnnual report

    「Our Nomination and Compensation Committee consists of 4 members, chaired by Representative Director and President Uehara Koki (上原 幸樹), and comprising Outside Director and Audit and Supervisory Committee Member Onishi Masaya (大西 雅也), Outside Director and Audit and Supervisory Committee Member Tsujii Kohei (辻井 康平), and Outside Director and Audit and Supervisory Committee Member Fukuchi Toshiyuki (福地 叔之). When the Board of Directors decides on executive appointments, compensation and other matters, the Nomination and Compensation Committee, an advisory body to the Board comprising a majority of outside directors, deliberates on the matters, and decisions are made through a process with greater transparency and objectivity.」

    For the first time, the company described a system in which a 4-member Nomination and Compensation Committee, with outside directors comprising a majority, deliberates on executive candidates and compensation and makes recommendations to the Board of Directors.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Stella Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Enhancing Transparency in the Executive Appointment Process through the Nomination and Compensation Committee | STELLA PHARMA CORPORATION (4888) | Komori